Showing results (21-30 of 63) with videos related to

Sort By:
Pageof 7
Gene Therapy|August 28, 2009
A modified E2F-1 promoter improves the efficacy to toxicity ratio of oncolytic adenovirusesJ J Rojas, M Cascallo, S Guedan, et al.
Gene Therapy|July 6, 2007
Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirusM Raki, T Hakkarainen, G J Bauerschmitz, et al.
Gene Therapy|December 6, 2013
CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune response and tumor imagingS Parviainen, M Ahonen, I Diaconu, et al.
Gene Therapy|April 11, 2008
Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodiesM Särkioja, S Pesonen, M Raki, et al.
Human Mutation|February 12, 2000
A novel splice site mutation of the EXT2 gene in a Finnish hereditary multiple exostoses family. Mutations in brief no. 197. OnlineM Wolf, A Hemminki, A Kivioja, et al.
Cancer Research|July 15, 1996
Semiautomated assessment of loss of heterozygosity and replication error in tumorsF Canzian, R Salovaara, A Hemminki, et al.
Gene Therapy|May 15, 2009
Ad5/3-9HIF-Delta24-VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic oncolytic adenovirus for kidney cancer treatmentK Guse, I Diaconu, M Rajecki, et al.
Gene Therapy|April 1, 2005
Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancerM Raki, A Kanerva, A Ristimaki, et al.
Gene Therapy|August 11, 2006
A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancerT Ranki, A Kanerva, A Ristimäki, et al.
Oncoimmunology|May 4, 2018
TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockadeV Cervera-Carrascon, M Siurala, J M Santos, et al.
Pageof 7